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Abstract
Objective. To compare survival outcomes between primary
surgery and primary radiation therapy (RT) in patients with
human papillomavirus (HPV)–negative oropharyngeal squamous cell carcinoma (OPSCC).
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Study Design. A retrospective observational cohort study.
Setting. National Cancer Database.
Methods. A National Cancer Database review was conducted of 2635 patients with HPV-negative OPSCC who
underwent surgery or RT 6 chemotherapy between 2010
and 2014. Univariate analysis was performed on all variables
and entered into a multivariate model. The main outcome
was overall survival (OS).
Results. A total of 2635 patients with HPV-negative OPSCC
were organized into 4 groups based on cancer staging. In
group 1 (T1-2 N0-1; n = 774), up-front surgery had significantly better 5-year OS (76.2%) than RT (56.8%; adjusted
hazard ratio [aHR], 1.76; P = .009; 95% CI, 1.15-2.69) and
chemoradiation therapy (CRT; 69.5%; aHR, 1.56; P = .019;
95% CI, 1.08-2.26). In group 2 (T3-4 N0-1; n = 327), no significant difference existed between surgery and CRT (5-year
OS, 51.3% vs 52.4%; aHR, 0.96; P = .88; 95% CI, 0.54-1.69).
In group 3a (T1-2 N2-3; n = 807), surgery with adjuvant
treatment showed significantly better 5-year OS than CRT
(78.6% vs 68.8%; aHR, 1.51; P = .027; 95% CI, 1.05-2.18). In
group 3b (T3-4 N2-3; n = 737), surgery with adjuvant treatment was not statistically associated with better 5-year OS
as compared with CRT (61.0% vs 43.7%; aHR, 1.53; P = .06;
95% CI, 0.98-2.39).
Conclusion. Primary surgery may provide improved survival
outcomes in many cases of HPV-negative OPSCCs. These
data should be used in weighing treatment options and may
serve as a basis to better delineate treatment algorithms for
HPV-negative disease.

O

ver 20 years, oropharyngeal squamous cell carcinoma
(OPSCC) has been divided into human papillomavirus (HPV) positive and HPV negative.1 HPVpositive OPSCCs have superior survival when compared with
HPV-negative counterparts.2 During this period, the majority
of new OPSCCs become HPV positive, and research efforts
have focused on this group.3 Data are scarce on survival outcomes for HPV-negative OPSCC.4-6
The eighth edition of the American Joint Committee on
Cancer (AJCC) staging system separates OPSCC by HPV
status.2-7 National Comprehensive Cancer Network (NCCN)
guidelines created separate algorithms based on HPV status.8
Despite this division, OPSCC types have similar recommendations for up-front surgery and nonsurgical approaches.8
Historically, survival data did not subgroup OPSCC by
HPV status.4,5,8 Based on several retrospective series, with
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85,743 patients (2004 – 2014)
(Patients with a primary oropharyngeal
cancer)

40,708 patients (2010 – 2014). Only those years included since HPV status was collected starting 2010.

Inclusion
Process

19,678 patients with a reported HPV status. 21,030 (51.66%) with a missing HPV status.

HPV negative=6,618 (33.63%) (Included).

5,892 patients
Surgery and/or Radiation
Excluded (3,257):
1. Unknown vital status or follow-up period.
2. TX, T0, Tis, and missing AJCC clinical Tclassification.
3. NX and missing AJCC clinical N-classification.
4. M1 and missing AJCC clinical M-classification.
5. Palliative care.
6. Primary site surgery without lymph node surgery.
7. Lymph nodes surgery only followed by radiation.
8. Non-standard or unknown treatment sequence.
9. Regional radiation dose ≤ 65 Gy or unknown.
10. Unknown chemotherapy status.
11. Missing value of any of the study parameters.

2,635 patients
Final Study Sample

Figure 1. Flowchart: systematic process used in the current study for patients’ inclusion and exclusion. Study population included patients with
squamous cell carcinoma (code 807 and primary site codes C019, C024, C051, C052, C090, C091, C098, C099, C100, C101, C102, C103,
C104, C108, and C109). AJCC, American Joint Committee on Cancer; HPV, human papillomavirus.

the hope of diminishing toxicity through organ preservation,1,2 it became a common notion that OPSCC is best treated
with chemoradiation therapy (CRT). However, these data
were likely skewed by the inclusion of HPV-positive disease.
Thus, the question remains: which treatment paradigm provides the best survival outcome for HPV-negative OPSCC
based on clinical staging?
The aim was to determine the overall survival (OS) differences in HPV-negative OPSCC by treatment modality. The
National Cancer Database (NCDB) was employed to obtain a
hospital-based cohort.

Methods
Data Source and Inclusion/Exclusion Criteria
The NCDB is a hospital-based registry collecting data from
.1500 Commission on Cancer–approved hospitals in the
United States. It captures 70% of newly diagnosed cancers.
The 2015 head and neck NCDB participant user file was
accessed; it contains patient demographics, cancer characteristics, treatment modalities, and OS. This study is exempt

from Institutional Review Board approval (University of
Florida).
From 2004 to 2014, 85,743 patients with OPSCC were registered in the NCDB. Oropharyngeal primary site codes were
selected: C019, C024, C051, C052, C090, C091, C098, C099,
C100, C101, C102, C103, C104, C108, C109. Since 2010,
19,678 patients with known HPV status were reported. The
inclusion/exclusion criteria are described in Figure 1. The
first-echelon inclusion criterion was OPSCC with HPVnegative squamous cell carcinoma histology (code 807;
International Classification of Disease for Oncology, Third
Edition); the remaining cases were excluded9 and 6618
patients remained. Next, patients with missing/unknown clinical TNM/AJCC staging, vital status, or follow-up were
excluded. M1 classification or patients under palliative care
were removed.
The second level of inclusion criteria defined curativeintent treatment based on the 2019 NCCN guidelines.8 This
included patients who underwent definitive primary surgery
or definitive primary radiation therapy (RT) 6 chemotherapy.
Definitive primary surgery was defined as wide local excision
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of the primary tumor with neck dissection. All other forms of
incomplete resection were excluded. These included codes 10
to 15, 90, and 99, which represent unknown surgical status,
partial tumor removal, excisional biopsy, or a combination of
non–curative intent modalities. None of these categories were
associated with neck dissection and likely represented various
forms of large biopsies (eg, tonsillectomy, base of tongue
mucosectomy, excisional lesion biopsy). These incomplete
resections did not include curative-intent surgery with positive margins. There was a separate column for margin status.
Those who underwent primary tumor resection without neck
dissection or a neck dissection without primary tumor resection before RT were also excluded. Patients with curativeintent RT 6 chemotherapy who had unknown RT dose, dose
\66 Gy, unknown or nonstandard RT delivery method,
unknown or nonstandard sequence of surgery-RT modalities,
or unknown chemotherapy status were excluded. The
sequence of treatment modalities was listed as surgery, RT,
CRT, or surgery followed by RT or CRT. A total of 2635
patient records remained for analysis.

Patient Groups
The NCCN guidelines stratify cases by T and N classifications
instead of overall staging.8 This allows multidisciplinary
groups to provide case-specific treatment options instead of
generalizing by early or late stage. The goal of this study was
to validate these algorithms and determine if recommendations correspond with optimal survival outcomes. Thus, the
study population was grouped by the same groups that the
NCCN guidelines use.
The study population was divided into 3 groups based on
NCCN treatment decision categories: group 1, T1-2 N0-1;
group 2, T3-4 N0-1; and group 3, T1-4 N2-3.8 Because T classification is often the first decision-making branch in the
NCCN algorithms and plays a major role in deciding treatment approach, the third group was split into 2 subcategories:
group 3a, T1-2 N2-3; group 3b, T3-4 N2-3. The reason for
this split is that the treatment options for T1-T2 and T3-T4 are
very different (ie, transoral surgery vs unilateral RT fields or
open surgery vs bilateral RT fields).

Treatment Packages
Based on highest level of evidence used by the NCCN (level
2a), appropriate treatment packages were included, and all
inappropriate options, as referenced by the NCCN (level 2b
and 3), were excluded.8 For example, single-modality treatment of surgery or RT from the cT3-4 groups was excluded,
and single-modality RT for group 3a (cT1-2 N2-3) was
excluded. Surgery only was included for cT1-2 N2-3 because
in many cases, the final staging was pT1-2 N0-1, and adjuvant
RT was not necessary.

Data Points
Demographics, tumor characteristics, and treatment details
were included. Age was dichotomized at the mean of 65
years. Race was classified as White/non-White. Insurance
status was classified as follows: no insurance and Medicaid or
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Medicare, private insurance, and governmental insurance.
Comorbidities were scored by Charlson-Deyo score: 0-1 or
2. Oropharyngeal subsites were classified as base of tongue,
soft palate, tonsil, and oropharyngeal walls. Lymphovascular
invasion data were collected where reported. Perineural invasion is not included in the NSDB and could not be reported.
Other factors known to influence survival (eg, smoking
status) were also not available. Clinical AJCC staging,
seventh edition, was used instead of pathologic staging to
allow direct comparison between surgical and nonsurgical
groups. AJCC staging, eighth edition, could not be used, as
extranodal extension is not coded in the NCDB. Staging was
based on clinical staging, as pathologic staging is not available in patients treated with RT. This allowed for comparisons
with a common baseline. Because treatment decisions
are founded on clinical staging, this was used to analyze
outcomes.

Statistical Analysis
Survival analysis was performed separately for each treatment
group. OS was defined as time between diagnosis and death
or end of follow-up. Median survival was estimated with the
Kaplan-Meier product limit method, and significant differences between survival times were determined with the logrank test. Independent prognostic factors for OS, hazard ratio
(HR), and 95% CI were calculated with Cox proportional
hazard models. A multivariate Cox HR model controlled
for age, sex, race, insurance status, comorbidity status, and
cancer site. Patients were analyzed in an intent-to-treat
manner and did not cross over between treatment groups. HR
.1 corresponded to worse OS (increased likelihood of death).
All tests were 2-sided with P \ .05 considered significant.
Patient, clinical, and treatment variables were selected a
priori. Statistical analyses were performed with SAS version
9.3 (SAS Institute Inc).

Results
A total of 2635 cases of HPV-negative OPSCC were included
(1983 men, 75.3%; 652 women, 24.7%): 774 in group 1 (T1-2
N0-1), 327 in group 2 (T3-4 N0-1), 807 in group 3a (T1-2 N23), and 727 in group 3b (T3-4 N2-3). Baseline characteristics
are shown in Table 1.
The mean 6 SD age was 59.7 6 9.8 years; 2260 were
White (85.8%) and 375 were non-White (14.2%). The median
follow-up time was 34.8 months (interquartile range, 15.453.2 months); .90% of patients were insured; and .80%
were comorbidity free (Table 1). Tonsil (n = 1163, 44.1%)
and base of tongue (n = 989, 37.5%) were the most common
subsites; soft palate was the least common (n = 175, 6.6%).
Lymphovascular invasion was reported in 35.4% of patients
(137 positive, 14.7%; 796 negative, 85.3%). Up-front surgery
pathologically upstaged 66 cases in clinical T classifications
(8.8%) and 63 in N classifications (8.4%).
Significant variables from the univariate analysis were
inserted into the multivariate Cox regression model. All variables showed significance (P \ .05) in the multivariate
model.
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Table 1. Study Population of Patients With Human Papilloma Virus–Negative Oropharyngeal Squamous Cell Carcinoma: National Cancer
Database, 2010-2014.a
AJCC clinical stage

Age, y
\65
65
Sex
Male
Female
Race
White
Non-White
Type of insurance
No insurance, Medicaid
Private, Medicare, other governmental
Charlson-Deyo score
0-1
2
Site of cancer
Base of tongue
Soft palate
Tonsil
Oropharyngeal walls
Treatment type
Surgery only
RT only
RT 1 CT only
Surgery 1 adjuvant RT/CT
T upstaged following surgeryc
Not upstaged
Pathologically upstaged
N upstaged following surgeryc
Not upstaged
Pathologically upstaged
Lymphovascular invasion
Negative
Positive

Study
population
(N = 2635)

Group 1:
T1-2 N0-1
(n = 774)

Group 2:
T3-4 N0-1
(n = 327)

Group 3a:
T1-2 N2-3
(n = 807)

Group 3b:
T3-4 N2-3
(n = 727)

1852 (70.28)
783 (29.72)

516 (66.67)
258 (33.33)

217 (66.36)
110 (33.64)

583 (72.24)
224 (27.76)

536 (73.73)
191 (26.27)

.005

1983 (75.26)
652 (24.74)

509 (65.76)
265 (34.24)

257 (78.59)
70 (21.41)

650 (80.55)
157 (19.45)

567 (77.99)
160 (22.01)

\.001

2260 (85.77)
375 (14.23)

687 (88.76)
87 (11.24)

278 (85.02)
49 (14.98)

717 (88.85)
90 (11.15)

578 (79.5)
149 (20.5)

\.001

527 (20)
2108 (80)

104 (13.44)
670 (86.56)

64 (19.57)
263 (80.43)

136 (16.85)
671 (83.15)

223 (30.67)
504 (69.33)

\.001

2517 (95.52)
118 (4.48)

730 (94.32)
44 (5.68)

306 (93.58)
21 (6.42)

783 (97.03)
24 (2.97)

698 (96.01)
29 (3.99)

\.001

989
175
1163
308

(37.53)
(6.64)
(44.14)
(11.69)

265
94
340
75

(34.24)
(12.14)
(43.93)
(9.69)

112 (34.25)
24 (7.34)
125 (38.23)
66 (20.18)

299 (34.25)
25 (7.34)
416 (38.23)
67 (20.18)

313
32
282
100

(43.05)
(4.4)
(38.79)
(13.76)

\.001

302
128
1751
454

(11.46)
(4.86)
(66.45)
(17.23)

263
128
226
157

(33.98)
(16.54)
(29.2)
(20.28)

0 (0)
0 (0)
292 (89.3)
35 (10.7)

39 (4.83)
0 (0)
562 (69.64)
206 (25.53)

0
0
671
56

(0)
(0)
(92.3)
(7.7)

\.001

682 (91.18)
66 (8.82)

375 (89.71)
43 (10.29)

685 (91.58)
63 (8.42)

368 (88.04)
50 (11.96)

796 (85.32)
137 (14.68)

365 (92.88)
28 (7.12)

P valueb

225 (92.98)
17 (7.02)

88 (83.81)
17 (16.19)

213 (78.31)
59 (21.69)

130 (79.75)
33 (20.25)

\.001

Abbreviations: AJCC, American Joint Committee on Cancer; CT, chemotherapy; RT, radiotherapy.
Note: The treatment is based on the level of evidence (level 2a) used by the National Comprehensive Cancer Network. Appropriate treatment packages were
included, and the inappropriate options, as referenced by the network (level 2b and 3), were excluded.
a
Values are presented as No. (%). Percentage values may not add up to 100% due to rounding.
b
Chi-square test.
c
Blank cells indicate not applicable due to the data use agreement stipulating that a sample size \10 should not be reported.
d
The treatment is based on the level of evidence (level 2a) used by the National Comprehensive Cancer Network. Appropriate treatment packages were
included, and the inappropriate options, as referenced by the network (level 2b and 3), were excluded.

Patients in group 1 (T1-2 N0-1), who received up-front surgery without adjuvant treatment as a reference, had significantly better 5-year OS (76.2%) than either RT (56.8%;
adjusted HR [aHR], 1.76; 95% CI, 1.15-2.69; P = .009) or
CRT (69.5%; aHR, 1.56; 95% CI, 1.08-2.26; P = .019).
Adding adjuvant treatment after surgery did not add any significant survival advantage when compared with surgery

alone (77.4%; aHR, 1.16; 95% CI, 0.74-1.84, P = .52). Treatment outcomes are in Table 2 and Supplemental Table S1
(available online). Kaplan-Meier analysis of survival by treatment modality for the 4 groups is in Figure 2.
In group 2 (T3-4 N0-1), 2 appropriate NCCN-recommended treatment regimens were used: surgery followed by
adjuvant treatment versus primary CRT.8 There was no
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Table 2. Overall Survival in Patients With Human Papillomavirus–Negative Oropharyngeal Squamous Cell Carcinoma Based on Treatment.
5-y overall survival, %

aHRa

95% CI

P value

RT/CT

76.15
56.79
69.53
77.39

Reference
1.76
1.56
1.16

1.15-2.69
1.08-2.26
0.74-1.84

.009
.019
.52

52.35
51.25

0.96
Reference

0.54-1.69

.88

RT/CT

1.71
1.51
Reference

0.85-3.46
1.05-2.18

.13
.027

RT/CT

72.10
68.78
78.59
43.72
61.02

1.53
Reference

0.98-2.39

.06

RT/CT

AJCC group: treatment type
T1-2 N0-1
Surgery only
RT only
RT 1 CT only
Surgery 1 adjuvant
T3-4 N0-1
RT 1 CT only
Surgery 1 adjuvant
T1-2 N2-3
Surgery only
RT 1 CT only
Surgery 1 adjuvant
T3-4 N2-3
RT 1 CT only
Surgery 1 adjuvant

Abbreviations: aHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; CT, chemotherapy; RT, radiotherapy.
a
Multivariate Cox hazard ratio model controlling for age, sex, race, insurance status, comorbidities status, and site of cancer.

Figure 2. Kaplan-Meier analysis of survival by treatment modality: (A-D) group 1, T1-2 N0-1; group 2, T3-4 N0-1; group 3a, T1-2 N2-3; group
3b, T3-4 N2-3.
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Table 3. Review of Literature.
No. of patients
First author

Year

Total

HPV–

Hobbs14

2017

357

39

Kelly10,a
Mahmoud11,a
Seikaly13

2017
2017
2015

1044
1873
279

1044
515
84

Zenga17

2015

131

34

Outcomes
Stage

Modalities

Survival

All

Surgery vs CRT

T1-2N1-2b
All
III and IV

Surgery vs CRT
TORS vs nonsurgical
Surgery with
adjuvant vs CRT

T4

Surgery vs
nonsurgical

%

DSS
OS
RFS
OS
3-y OS
5-y DSS (smokers)

56 vs 19
50 vs 19
—
HR, 1.01
84 vs 66
60.3 vs 27.4

5-y DSS (nonsmokers)
OS (smokers)
OS (nonsmokers)
OS, DSS, DFS

100 vs 80
43.1 vs 20.8
85.7 vs 60
Surgery better
with significant DFS

P value
.04
.058
.22
.93
.01
\.001
.009
.003
.24
.1, .15, .049

Abbreviations: CRT, chemoradiation; DFS, disease-free survival; DSS, disease-specific survival; HPV, human papillomavirus; HR, hazard ratio; OS, overall survival;
RFS, recurrent-free survival; TORS, transoral robotic surgery.
a
National Cancer Database.

significant difference in 5-year OS between them (51.3% vs
52.4%; aHR, 0.96; 95% CI, 0.54-1.69; P = .88; Table 2 and
Supplemental Table S2, available online). In group 3a (T1-2
N2-3), patients who received surgery with adjuvant treatment
had significantly better 5-year OS than primary CRT (78.6%
vs 68.8%; aHR, 1.51; 95% CI, 1.05-2.18; P = .027). Surgery
alone had worse 5-year OS than surgery with adjuvant treatment (72.1% vs 78.6%); this difference was not significant
(aHR, 1.71; 95% CI, 0.85-3.46; P = .13; Table 2 and Supplemental Table S3).
In group 3b (T3-4 N2-3), surgery with adjuvant treatment
had substantially better 5-year OS than primary CRT (61.0%
vs 43.7%), but this was not statistically significant (aHR,
1.53; 95% CI, 0.98-2.39; P = .06; Table 2 and Supplemental
Table S4, available online). Population at risk of mortality as
classified by stage and type of therapy was calculated and is
shown in Supplemental Table S5. A parallel analysis was performed through pathologic T/N classifications, and the results
are shown in Supplemental Table S6.

Discussion
T1-T2 HPV-negative OPSCCs appear to have improved OS
with primary surgical approaches. This is the first study to use
a large population database to demonstrate this. While this
was not the first study to use a national hospital-based registry
to study HPV-negative OPSCC, it is the first to stratify
patients by best practice treatment modalities per national
guidelines.10,11
Group 1 (T1-2 N0-1), surgery alone had significantly
better 5-year OS than RT or CRT (7% to 19% improvement).
Adding adjuvant treatment to surgery did not have any significant benefit, which parallels the results of Yuan et al.12 They
analyzed 114 patients treated with primary surgery for HPVnegative OPSCC. Disease-specific survival was affected by
adjuvant RT in stages III and IV but did not show any benefit

in stages I and II.12 It is thought that many of these patients
will have borderline or minimal indications for adjuvant treatment and will not receive additional benefit from postoperative RT. For example, in some patients, N1 status will provide
a debatable indication for adjuvant treatment.10,12-14 A comparative literature review is shown in Table 3.
For group 3a (T1-2 N2-3), surgery followed by adjuvant
treatment showed significantly better 5-year OS than primary
CRT (10% improvement). Kelly et al compared up-front surgery versus nonsurgical modalities in HPV-negative OPSCC
within the NCDB, but they did not include N0, N2c, and N3 in
their study.10 Their data were limited to 2010 to 2012 and followed the RTOG 1221 (NCT01953952) design, which
attempted to randomize patients with cT1-2 N1-2b HPVnegative OPSCC to transoral robotic surgery or CRT but
closed due to a lack of accrual. The total population of T1-2
N1-2b was 1044 patients; there was no significant OS difference between patients with up-front surgery 460 (44.1%) and
patients with CRT 584 (55.9%). The current study stratified
patients by NCCN algorithms to compare results with national
guidelines. In groups 1 and 3b together (T1-2 N0-1/T1-2 N23), there were 1581 patients: 665 (42%) had surgery, 128
(8%) received RT, and 788 (50%) underwent CRT. Up-front
surgery in both groups had significantly better survival than
nonsurgical options (P \ .05). These results differ from Kelly
et al and may be explained by the groups having different
TNM and that all forms of incomplete surgery were
excluded10 (Table 3). Additionally, there may have been
some inherent biases, such as health status and tumor site (eg,
tonsil cancers are much ‘‘easier’’ to excise than base of
tongue). To best account for these factors, the Cox regression
analysis included them as controls.
In group 3a (T1-2 N2-3), patients treated with surgery only
had statistically similar survival to those who were treated
with adjuvant therapy. This likely demonstrates the accurate
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staging value of surgery. With final pathology results, some
cases were downstaged, and patients did not meet indications
for adjuvant treatment. Conversely, some cases were upstaged,
and patients required adjuvant treatment to maintain a similar
survival to their counterparts treated with surgery only. This is
similar to previous literature examining how final pathology
influences adjuvant treatment and survival.10-14
Apart from Kelly et al, our findings are consistent with
most literature. Comparison is difficult because each study
followed a different stratification approach. For example,
some studies used TNM (T1-2 N1-2b; Kelly et al), and other
studies (Seikaly et al) used overall staging10,13 (Table 3).
Like Kelly et al, Mahmoud et al used the NCDB. They analyzed 515 HPV-negative cases and found that patients undergoing primary transoral robotic surgery had significantly
better 3-year OS than those treated via nonsurgical modalities
(84% vs 66%, P = .01). But they did not stratify the HPV-negative population according to staging; rather, the cohort
included patients with HPV-negative and HPV-positive
OPSCC.11 Seikaly et al studied 84 patients who had HPVnegative OPSCC with stage III/IV disease; in univariate analysis, primary surgery with adjuvant treatment yielded significantly better 5-year disease-specific survival and OS (72.0%
and 54.8%, P \ .001) than primary CRT (37.1% and 27.6%,
P \ .001). Multivariate analysis showed a significant survival
advantage with surgical treatment.13 Hobbs et al showed that
surgery with adjuvant treatment had improved diseasespecific survival (HR, 0.43; P = .015) and OS (HR, 0.49; P =
.26) than CRT in 26 patients14 (Table 3). These data are consistent with our study.
For group 2 (T3-4 N0-1), patients with up-front surgery
and adjuvant treatment did not have survival benefit over
those who received primary CRT. The lack of statistical difference is likely due to the control rates for N0 and N1 being
similar for surgery and CRT.15
In group 3b (T3-4 N2-3), primary surgery with adjuvant
treatment had 17.3% better 5-year OS than CRT and neared
significance (P = .06). Surgical approaches for T3-4 disease
often carry a higher risk of positive margins and complications, which also affect survival.16 The advanced neck disease
could be the reason for a survival advantage with surgery in
T3-4 N2-3. For most head and neck cancer sites, advanced
neck disease is best cured with surgery plus adjuvant treatment.15 This was similar to 34 patients with T4 HPV-negative
OPSCC in the study by Zenga et al. OS and disease-specific
survival were higher in the surgical group without statistical
significance (x2 = 2.649, df = 1, for log-rank P = .10 and x2 =
2.077, df = 1, for log-rank P = .15, respectively), but diseasefree survival was significantly higher in patients treated with
primary surgery (x2 = 3.869, df = 1, for log-rank P = .049;
Table 3).17
It is prudent to remember that surgery functions as a tool of
diagnosis/prognosis. In this study, surgery upstaged .10% of
T/ N clinical classifications in group 1 (T1-2 N0-1). The result
was more intensified adjuvant treatment. If a nonsurgical
modality were used, it would likely have been RT only, which
may not have provided as high a cure rate.18 It was determined
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that patients in groups 2 to 3b faired worse when pathologic
staging was used to analyze OS. It is likley that patients who
had worse pathology received adjuvant therapy. However, the
adjuvant therapy in these cases did not seem to make much of
a difference. The only patients who did better in this scenario
were those with early-stage OPSCC (group 1). Thus, when a
treatment option for more advanced disease is being chosen,
these factors must be considered.
Although many patients with HPV-negative OPSCCs can
have improved survival with primary surgery, this must be
taken into context with functional and quality-of-life outcomes.
While a small tonsil primary may do very well functionally
with surgery, a deep base of tongue primary may require a total
glossectomy and may do very poorly with surgery. The results
of this study suggest that surgery should be a part of the discussion in treatment recommendations, but recommendations
should strive to balance survival with functional outcomes and
quality of life. Each case is unique, and a multidisciplinary discussion is needed to tailor treatment for each patient.

Limitations
The NCDB does not allow control for all confounding factors.
Some variables known to influence survival are not in the
database, such as perineural invasion, extranodal extension,
and smoking status. These must be taken into consideration
when interpreting results as they may influence treatment
decisions. This is especially true for extranodal extension,
which has such a strong influence on survival that it was
added into the eighth edition of the AJCC staging system. OS
is a crude measure of treatment efficacy; it is determined by
death from any cause, and there are many competing causes
of death in cases of OPSCC. Although the multivariate analysis controlled for comorbid status (Charlson-Deyo score), it is
possible that healthier patients were selected for primary surgery. This could account for the large difference in OS for
group 3b. In that group, few patients had primary surgery
versus CRT, and the unaccounted-for variable could be hiding
in other health conditions. The other possibility is that functional outcomes were not taken into account and surgery was
not offered to patients with larger tumors.
Although the NCDB is the largest cancer database in the
United States, the accuracy of registration can be limited. In
gathering records, the number of patients dropped from 6618
to 2635; almost two-thirds of the population were omitted to
provide complete data that met study criteria. This may have
created selection bias; however, without application of study
criteria, data would be too heterogeneous to have meaning. The
study included the most complete and accurate data possible.
We excluded modalities with less evidence-based application by the NCCN (eg, induction chemotherapy). Although
Sher et al showed that induction chemotherapy had significant
benefit for highly advanced HPV-negative OPSCC (T4N3),
these results have not been reproduced.19 Also, we could not
stratify patients by type of surgery (transoral vs open) because
this variable was not accurately registered.
To promote individualized patient-centered care, the
patient’s preferences should be considered. The patient
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should certainly be educated regarding survival differences
and the pros and cons of each treatment pathway. The patient
has the right to choose options that show lower survival rates
to avoid the highly morbid options. Major long-term RT complications, such as osteoradionecrosis and dysphagia, need to
be considered.20,21
A randomized clinical trial would be needed to determine
the optimal treatment modality for HPV-negative OPSCC.
Unfortunately, it is difficult to enroll patients in trials with
surgical and nonsurgical arms as shown by RTOG 1221. In
the absence of randomized prospective data, national database
analyses can be the next available level of evidence.

Conclusion
Primary surgery may provide improved survival outcomes for
many HPV-negative OPSCCs. These data may be used in
weighing treatment options with patients and may help better
delineate treatment algorithms for HPV-negative disease.
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